Needham & Company Downgrades Optimer Pharmaceuticals (OPTR) to Hold on Weaker Dificid Sales; Says Takeover Hopes Dim May 10, 2013 07:35AM
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Generic Vancomycin in U.S. Appears to have Minimal Impact Sep 6, 2012 09:20AM
Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Raising Q4 on Dificid Use in Medicare In-Patient Cases Aug 3, 2012 10:36AM
Needham & Company Defends on Optimer (OPTR); Favorable Long-Term Trend Intact Aug 1, 2012 08:00AM
Needham & Company Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); Q2 Preview Jul 18, 2012 01:03PM


May 11, 2012 08:18AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Dificid Hits Sales Goal under Cubist Collaboration
Apr 9, 2012 03:00PM Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Mgmt Changes Not Related to Dificid
Mar 8, 2012 07:50AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Q4 Dificid Sales In Line.
Mar 6, 2012 07:24AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Adjusted Estimates Ahead of Q4 Results
Jan 6, 2012 10:34AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); 2012 Preview
Dec 23, 2011 07:35AM Needham & Company 2012 Biotech Preview
Dec 6, 2011 07:47AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Investor Day Review
Sep 29, 2011 01:15PM Needham & Company Reiterates 'Buy' on Optimer Pharmaceuticals (OPTR); Collaborator/Competitor Cubist Confirms Plans to Bring CB-315 into Phase 3
Sep 22, 2011 02:52PM Needham & Company Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); Dificid Growth Offers Further Appreciation in Stock Price
Sep 22, 2011 02:13PM Needham & Company Maintains a 'Buy' on Cubist Pharmaceuticals (CBST); Favorably Inclined Towards the Stock
May 31, 2011 10:31AM Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Dificid Approved by the FDA
Apr 6, 2011 09:39AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Positive Discussion at Fidaxomicin FDA AdCom Meeting, Expect Approval Next Month
Apr 1, 2011 11:26AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR): Fidaxomicin FDA Briefing Documents Encouraging; Expect Favorable AdCom Review Next Week
Apr 1, 2011 11:05AM Morning Movers 04/01: (HRZ) (IRE) (ALEX) Higher; (OMER) (EXFO) (CDTI) Lower
Mar 11, 2011 08:13AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); 4Q10 Review. We Expect Favorable AdCom in April, Followed by Fidaxomicin Approval in May
Jan 6, 2011 08:40AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); 2011 Preview.
Nov 17, 2010 07:37AM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Update on the C. difficile Commercial Opportunity for Fidaxomicin
Apr 12, 2010 12:37PM Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Encouraging Phase 3 Fidaxomicin Recurrence Data
Jul 29, 2009 02:54PM Needham Upgrades Optimer Pharmaceuticals (OPTR) to Buy
May 18, 2009 02:40PM Optimer Pharma (OPTR) Stock Slips on Numerous Analyst Downgrades
Jul 1, 2008 08:49AM Needham Starts Optimer Pharmaceuticals (OPTR) at Buy